Wednesday, November 1, 2017

Alpha-1 Antitrypsin (AAT) Deficiency

Alpha-1 antitrypsin (AAT) deficiency is an inherited disorder, most prevalent in populations of European ancestry, and is underdiagnosed. It results from mutations in the SERPINA1 gene, leading to either a reduced level or function of the AAT protein. AAT deficiency results a variety of health issues, particularly predisposition to the development of liver and lung disease1. When exacerbated by smoking, this results in damage to the alveoli and ultimately emphysema with many of the features of COPD1.

The recently published Alpha-1 Antitrypsin deficiency, in the Methods in Molecular Biology series (Springer Protocols) provides a comprehensive background to this disease and state-of-the-art methods2, including a chapter outlining the use of the forced oscillation technique to assess lung structure and function relationships, with focus on the flexiVent3.



Recent years have seen exciting developments in both the development of animal models for AAT deficiency research and proof of principle studies for treatment approaches. Using adeno-associated virus 2/8 to direct gene delivery specifically to mouse lung Payne et al were able to demonstrate not only elevated serum AAT but also protection against elastase-induced augmentation of compliance – measured using the forced-oscillation technique (FOT) on the flexiVent4.

Cox et al. performed pressure-volume loops and utilised the FOT with the flexiVent to confirm the increased compliance, with LPS challenge, of a newly developed mouse model of AAT deficiency. Generated using CRISPR/Cas9 genome editing, the model demonstrates many of the hallmark features of the human disease5

With the development of animal models which more closely resemble human disease, progress in the search for effective treatments will be greatly accelerated. SCIREQ looks forward to helping provide tools for this research.


1- Stoller, James K., and Loutfi S. Aboussouan. “A Review of α1-Antitrypsin Deficiency.”American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 3, 2012, pp. 246–259., doi:10.1164/rccm.201108-1428ci.
2- Borel, F., & Mueller, C. (Eds.). (2017). Alpha-1 Antitrypsin Deficiency (Vol. 1639). New York, NY: Springer New York. https://doi.org/10.1007/978-1-4939-7163-3
3- Parameswaran H., Suki B. (2017) Assessing Structure–Function Relations in Mice Using the Forced Oscillation Technique and Quantitative Histology. In: Borel F., Mueller C. (eds) Alpha-1 Antitrypsin Deficiency. Methods in Molecular Biology, vol 1639. Humana Press, New York, NY
4- Payne, J., Takahashi, A., Lonza, G., Balazs, A., Suki, B., Kotton, D. and Wilson, A., “Lung-Directed Gene Delivery Of Alpha-1 Antitrypsin Using Intratracheal Adeno-Associated Virus 2/8 In A Mouse Model Of Emphysema”, Poster presented at: ATS 2014, D38 Update in alpha one deficiency, May 21st, 2014, San Diego, U.S.A.
5- Cox, A., Borel, F., Li, W., Brodsky, M. and Meuller, C., “Simultaneous disruption of five serpinA1 genes in mice using CRISPR/Cas9 to generate the first animal model of alpha-1 antitrypsin deficiency”, Poster presented at the American Society of Gene & Cell Therapy 18th Annual Meeting, American Society of Gene & Cell Therapy 18th Annual Meeting, Gene Targeting and Gene Correction II, May 14th 2015, New Orleans, U.S.A.

Tuesday, October 24, 2017

Dose rather than concentration

Bronchoprovocation is a pulmonary function test frequently performed in patients as a diagnostic or therapy management tool.  It assesses the subject’s level of airway responsiveness following increasing aerosol challenges of methacholine, a direct bronchoconstrictive agent.  

Recently, the European Respiratory Society (ERS), in collaboration with the American Thoracic Society (ATS), updated their guidelines relative to this test.  The most significant modification made was the recommendation that the test outcome be expressed in terms of the dose delivered rather than as the concentration of the solution loaded into the nebulizer1.  The ERS guidelines state that this updated end-point reporting allows for comparable results from different devices or protocols, since the dose concept can account for delivery variations2


Methacholine challenge tests are also performed at the pre-clinical level.  There, the notion of delivered dose was introduced earlier3 and researchers who have been using the flexiVent FX system have known for some time the effectiveness of this now recommended clinical procedure or its impact on study comparison.  Indeed, with the push of a button, the operating flexiVent software can automatically generate a delivered dose estimate for each subject and aerosol challenge.  The dose calculation is based on specific nebulizer, subject, and system characteristics and imposes no restrictions on the experimental protocol nor does it require additional pieces of equipment.  The delivered dose estimate thus offers an important standardization to the preclinical assessment of airway responsiveness that now coincides with the most recent clinical recommendations. 

Contact us for more information on the delivered dose concept.  Our application specialists will be happy to answer your questions or assist you to improve your study.

Contact Us
Phone: 1.514.286.1429 | Toll Free 1.877.572.4737
Email: info@scireq.com


READ MORE
1Coates, Allan L., et al.  2017.  ERS technical standard on bronchial challenge testing: general considerations and        performance of methacholine challenge tests.  European Respiratory Journal 49 (5): 1601526.
2Coates, Allan L., et al.  2017.  The PD 20 but not the PC 20 in a methacholine challenge test is device independent.  Annals of Allergy, Asthma & Immunology 118 (4): 508-509.
3Robichaud, Annette, Liah Fereydoonzad, and Thomas F. Schuessler.  2015.  Delivered dose estimate to standardize airway hyperresponsiveness assessment in mice.  American Journal of Physiology-Lung Cellular and Molecular Physiology 308 (8): L837-L846.

Thursday, October 19, 2017

Great success at JAX Workshop on Phenotyping Mouse Models of Human Lung Disease

After a year of absence, the well-established Workshop on Phenotyping Mouse Models of Human Lung Disease returned last week in Bar Harbor, ME.  As in the past, SCIREQ was a partner in this year's event, in collaboration with the Jackson Laboratory Educational Program.


The course, which offers great learning and networking opportunities, contains both a theoretical and a practical part and covers various topics relevant to respiratory research.  Two laboratory sessions on lung function measurements are typically included in the event schedule.  During these sessions, the participants are divided into small groups, where they can interact with key leaders in the field, such as Dr Wayne Mitzner (John Hopkins Bloomberg School of Public Health) or Dr Lennart K. A. Lundblad (The University of Vermont), while learning about state-of-the-art techniques.


This renowned scientific event catering to the needs of pre-clinical researchers from around the world was fully attended this year.  We will be there next time.  We hope you will be there too!

For more information on SCIREQ or its products for respiratory research applications, please visit our website at www.scireq.com.

Wednesday, October 18, 2017

Biennale Pneumologie 2017 et CQSR

Merci aux organisateurs et à tous les participants de la Biennale Pneumologie 2017 et du CQSR, qui a eu lieu dans la magnifique ville de Québec. Nous avons particulièrement apprécié le volet sur la recherche fondamentale appliquée, où nous avons pu assister à des présentations sur l’asthme, la fibrose kystique, la SDRA et les MPOC (pour les Québécois) ou BPCO (pour les Français)   J

emka TECHNOLOGIES et SCIREQ sont fières de travailler avec les chercheurs francophones qui étudient sur le système respiratoire et les maladies cardio-pulmonaires.

Au plaisir de vous revoir à la Biennale 2019.


Liens :







Thursday, October 12, 2017

Workshop on Eosinophils in Allergy and Related Diseases – Tokyo, Japan

Will you be attending the 31st Workshop on Eosinophils in Allergy and Related Diseases in Tokyo? If so, come and meet with our partner emka TECHNOLOGIES Japan and see our solutions for your research.

Workshop Information
Date:         21st October 2017
Time:        10:00 am - 17:00 pm
Location:  Tokyo, Japan
Chairman: Dr. Hiroshi Nakajima, Allergy & Clinical Immunology, Chiba University
                 Hospital
Director:    Dr. Makoto Nagata, Allergy Center, Saitama Medical University


More information from previous workshops on this topic:

Tuesday, August 22, 2017

Deep inflations and their role in reproducible lung function measurements

Reproducibility is more than ever an inevitable topic in research.  Recently, the subject was addressed by Dr. Jason Bates1 specifically in relation to preclinical lung function measurements. 

As explained in this interesting article, lung function measurements are affected by a number of confounding factors and controlling for them ensures that the subjects are studied under the same conditions, which helps generate robust data that can be reproduced by others. 

According to Dr. Bates, controlled experimental conditions including anaesthesia and mechanical ventilation are needed to achieve high-quality preclinical lung function data1, 2.  However, it is known that under these conditions, there is a progressive loss in lung volume due to airway closure or collapse3.  Additionally, as can be seen in a number of studies, once closed, airspaces do not spontaneously re-open.  A high-pressure manoeuver, such as a deep lung inflation, is typically required to open-up closed airways4, 5 or completely collapsed lungs6.  Therefore, as reported in the article at hand1, it is key to start a preclinical lung function experiment with a deep inflation to standardize lung volumes across subjects at baseline. 

DEEP INFLATION

Technical Description
  • The deep inflation gradually inflates the subject’s lungs to a pressure of 30 cmH2O over a period of 3 seconds.
  • The lungs are then held at that pressure for another 3 seconds, time during the alveolar pressure is allowed to equilibrate to the applied pressure.
  • The initial and end volumes are used in the calculation the inspiratory capacity (IC).
Physiological Description
  • The Deep Inflation perturbation brings the subject’s lungs from end of expiration (FRC) to total lung capacity (TLC), which is defined by default as a pressure of 30 cmH2O.
  • It provides a direct measurement of the subject’s inspiratory capacity.
For more information on the deep inflation and other manoeuvers questions linked to preclinical lung function measurements or scientific equipment for respiratory research, please visit SCIREQ website - Knowledge Center or contact one of our applications specialists.  We will be happy to work with you to enhance the reproducibility of your research.

References
1.       Bates, JHT.  2017.  CORP: Measurement of lung function in small animals.  J Appl Physiol, in press, DOI: 10.1152/japplphysiol.00243.2017.
2.       Bates JH, Irvin CG.  2003.  Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 94: 1297-306.
3.       Mead J, Collier C.  1959.  Relation of volume history of lungs to respiratory mechanics in anesthetized dogs.  J Appl Physiol 14: 669-678.
4.       Wagers S, Lundblad LK, Ekman M, Irvin CG, Bates JH.  2004.  The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?  J Appl Physiol 96: 2019-27.
5.       Shalaby KH, Gold LG, Schuessler TF, Martin JG, Robichaud A.  2010.  Combined forced oscillation and forced expiration measurements in mice for the assessment of airway hyperresponsiveness.  Respir Res 11: 82.
6.       Limjunyawong N, Fallica J, Horton MR, Mitzner W.  2015.  Measurement of the pressure-volume curve in mouse lungs. Journal of visualized experiments: J Vis Exp 95: 52376.

Monday, August 21, 2017

WORKSHOP ON PHENOTYPING MOUSE MODELS OF HUMAN LUNG DISEASE

Do not miss the opportunity to learn key laboratory techniques used in respiratory research by attending the workshop on Phenotyping Mouse Models of Human Lung Disease hosted by the Jackson Laboratory. This workshop will take place from October 9-14, 2017 in beautiful Bar Harbor, Maine.
Participants completing this workshop will acquire a working knowledge of basic pulmonary biology and the pathophysiology/histopathology accompanying lung diseases. As in the past, SCIREQ’s Senior Scientist, Annette Robichaud will supervise some laboratory sessions on lung function measurements using state-of-the art techniques.

Hands-on laboratory sessions will cover: 
» Airway hyper-responsiveness (AHR) measurement using flexiVent
» Sampling techniques (lung lavage & bone marrow)
» Lung volume and pressure-volume (PV) curves
» Lung morphometry and stereology
» Pulmonary diffusing capacity
» Intubation and tracheostomy
» Lung histopathology


For additional information and to register, go to:
https://www.jax.org/Lung

Space is limited. Early enrollment is advised.

Thursday, July 27, 2017

15th International Symposium on Sleep & Breathing - THANK YOU!

We would like to extend a warm THANK YOU to the organizers of the 15th International Symposium on Sleep & Breathing that took place last week in Madison, Wisconsin and its participants. SCIREQ Inc. was proud to participate in this event and thus contribute to the next generation of leading scientists.


The Meeting’s Focus
The meeting’s tradition is a focus on trainees and junior faculty. Senior investigators sponsor junior investigators to present original research and receive constructive feedback. The most meritorious papers are selected for prestigious awards, including the Ann Suratt Award. The exceptional science presented never fails to generate animated discussions, which are further extended in an informal setting, as part of the evening social events where local history, music, dance and culinary culture are highlighted.1

Website:115th International Symposium on Sleep & Breathing.”The Meeting’s Focus” https://www.sleepandbreathing2017.org/history 

Monday, June 5, 2017

Thank you - ISAM 2017

SCIREQ attended the 21st International Society for Aerosols in Medicine (ISAM) Congress in Santa Fe. The event is focused on aerosol research, pulmonary drug delivery and inhalation toxicology. We demonstrated our respiratory research equipment with scientists, highlighting our new inExpose E-cigarette Research Extension

We thank the many researchers who came by to discuss their in vivo respiratory mechanics and inhalation exposure research.



Not at the conference? We are always available to answer any questions you may have. Please contact us at info@scireq.com or call us toll free at 1.877.572.4737. We also have a team worldwide who can help you with your research needs. Find out more by visiting our website: www.scireq.com/worldwide-distribution.




Wednesday, May 31, 2017

World No Tobacco Day

Every year, on 31 May, WHO and partners mark World No Tobacco Day (WNTD), highlighting the health and additional risks associated with tobacco use, and advocating for effective policies to reduce tobacco consumption.

The theme for this year's World No Tobacco Day is "Tobacco – a threat to development." It proposes measures that governments and the public should take to promote health and development by confronting the global tobacco crisis.1

  
The harmful effects of tobacco smoke exposure are well documented. Yet research is still necessary to understand the underlying pathophysiological mechanisms and there is a pressing need for new therapeutic agents to treat patients. Scientific evidence is also needed to understand the risks associated with vapour exposure from electronic cigarettes (e-cigarettes) in order to guide the decision-making process for the use of these nicotine delivery devices. The rapid adoption of e-cigarettes, especially amongst the youth, has spurred a rush to fill the knowledge gap pertaining to the safety profile for the users and the environment.

SCIREQ Related Products for
Tobacco Studies, E-Cigarettes & Vaping


The inExpose is a versatile, programmable, and compact exposure system that can be configured with smoke generation devices (e.g. cigarette smoking robot, single cigarette chamber, e-cigarettes), or nebulizers to generate a wide range of exposures consistently within and between studies, as well as across laboratories.

The E-cigarette extension is designed for the push button 3rd generation “MOD” e-cigarettes. This extension allows for longer exposures due to a larger tank, offers automated activation, custom puff profiles, and temperature control of the vapour produced.


The flexiVent system combines a wide selection of lung function measurements within a single device, while offering the sensitivity to capture small but significant changes. Overall and detailed respiratory mechanics, specific lung volumes, pressure-volume or flow-volume loops are examples of measurements used in tobacco or e-cigarette related studies with some outcomes (FEV, lung volumes) also having a translational value. 

To learn more about our products and how they may provide insight into tobacco related diseases or other applications, please contact info@scireq.com.

References 

1World Health Organization. "Tobacco - a threat to development" http://www.who.int/campaigns/no-tobacco-day/2017/en/

Tuesday, May 30, 2017

ATS 2017 - Thank you!

Thank you to everyone who visited our booth at ATS 2017 in Washington last week! It was a successful conference and we look forward to seeing you all again next year.




We also had a great time celebrating the 20th anniversary of the flexiVent during our yearly breakfast event.  A special THANK YOU to our presenters! It was due to their contribution, that the event was well attended and received very positive feedback. 


We are looking forward to future scientific and technological advances that will help researchers learn and better understand pulmonary function.

Your SCIREQ Team!

Thursday, May 11, 2017

Cystic Fibrosis

Cystic Fibrosis (CF) is an inherited autosomal recessive disease resulting from mutations in the CF Transmembrane conductance Regulator (CFTR) gene. CF patients progressively develop a pronounced respiratory phenotype, as the absence of CFTR function in the lung is associated with the thickening of secretions as well as the inability to properly excrete or clear them. This leads to bacteria accumulation and eventually bronchiectasis, allergic bronchopulmonary aspergillosis, and even respiratory failure.


The identification of the CFTR gene in the late 1980s propelled CF research1.  CFTR was identified as a chloride channel and knockout mice were generated, but the early phenotyping studies lacked the sensitivity required to quantify respiratory changes in these mice. It wasn’t until the detailed respiratory mechanics of the flexiVent that the first respiratory CFTR phenotype was reported2.  Various preclinical models of CF are now available3-5 to study the pulmonary manifestations of the CF disease and respiratory mechanics remain an important study outcome in that field.

There is also mounting evidence that CFTR plays a direct role in the airway smooth muscle6. Measuring the reactivity of isolated tracheal rings or strips ex vivo, in tissue baths, allows for a functional assessment in absence of external influences.  This approach was taken to study the effect of CFTR function on human airway smooth muscle and to confirm its role in bronchorelaxation6.



The emka & SCIREQ team will be attending the American Thoracic Society’s 2017 conference in Washington, DC! Come visit our booth #1731 and speak with our experienced team about our solutions for preclinical pediatric research.

1Identification of the cystic fibrosis gene: chromosome walking and jumping – Rommens et al. Science 245: 1059, 1989.
2 The “Goldilocks Effect” in Cystic Fibrosis: Identification of a lung phenotype in cftr knockout and heterozygous mouse – Cohen et al. BMC Genetics., 5: 21, 2004.
3Air trapping and airflow obstruction in newborn cystic fibrosis piglets – Adams et al. Am J Respir Crit Care Med 188: 1434, 2013.
4Lung phenotype of juvenile and adult cystic fibrosis transmembrane conductance regulator knockout ferrets – Sun et al. Am J Respir Cell Mol Biol 50: 502, 2014.
5Early pulmonary disease manifestations in cystic fibrosis mice – Darrah et al. Journal of Cystic Fibrosis 15: 736, 2016.
6Bronchorelaxation of the human bronchi by CFTR activators – Norez et al. ‎Pulm Pharmacol Ther 27: 38, 2014.

Tuesday, May 9, 2017

Sudden Infant Death Syndrome

Sudden infant death syndrome (SIDS) relates to the sudden and unexplained death of infants, typically during sleep. The cause is currently unknown, although it is thought to be linked to the neuronal control of breathing, particularly to the infant’s ability to respond to external stressors. It is also recognized that environmental factors (e.g. sleeping position, surface material, room temperature, second-hand smoke exposure) can increase the risk, along with other factors such as respiratory infections, gestational age at birth, or genetic disorders.


Changes in the breathing pattern can be an early indicator of the infants’ cardiovascular and respiratory systems inability to respond to external stresses, such as elevated CO21.  In preclinical research, breathing patterns can be tracked in conscious and unrestrained subjects for extended time periods using whole body plethysmography. This can be done in absence or presence of known external stressors, making this system an ideal tool to study SIDS models. Inserts are also available for neonate subjects so that ventilatory parameters can be studied as early as 2-3 days after birth.


Approximately 10-15% of all SIDS cases can be linked to ion channel mutations leading to fatal cardiac arrhythmias. Electrocardiogram (ECG) recordings can track the onset of ectopic beats and ventricular tachycardia, which can directly lead to sudden death2. Invasive or surface ECG recordings can be used to detect and quantify arrhythmias in newborn subjects to study SIDS.

Speak with our experienced team about your research during the American Thoracic Society’s 2017 conference.  Take the opportunity to visit the emka & SCIREQ booth  #1731 and learn more about our different solutions for your preclinical research.


1The Cerebellum and SIDS: Disordered Breathing in a Mouse Model of Developmental Cerebellar Purkinje Cell Loss during Recovery from Hypercarbia – Calton et al. Front Neurol. 7:78, 2016.
2Sudden Infant Death Syndrome in Mice with an Inherited Mutation in RyR2 – Mathur et al. Circ Arrhythm Electrophyisiol. 2:677, 2009

Thursday, May 4, 2017

Bronchopulmonary Dysplasia

Bronchopulmonary dysplasia (BPD) is a pediatric respiratory disorder that affects preterm infants who experienced respiratory distress. The distress can be treated with artificial surfactant administration and hyperoxia which leads to impaired growth of the lung due. BPD will begin to manifest as inflammation and vascular changes in the lungs1.


A common model of preclinical BPD uses hyperoxic exposure an early stage of life to alter the development of the subject’s lungs. Using conscious, unrestrained term or preterm subjects in a whole body plethysmography chamber allows for longitudinal measurements of ventilatory parameters, while also enabling controlled mixing and delivery of gases to generate a reproducible hyperoxic environment. Whole body plethysmography provides an ideal set-up to generate a model and track changes in the ventilatory parameters simultaneously.

Hyperoxia induced BPD leads to airway remodeling and airway hyperresponsiveness in early adulthood2. Changes in the tissue properties of the subject can reflect changes due to the effects of hyperoxia on lung development3. The flexiVent is a small animal ventilator that measures detailed respiratory mechanics. With the use of an integrated nebulizer, automated dose responses capturing the mechanical properties of the lung can separate naïve and BPD subjects, and potentially show separation within the treated groups due to disease severity.


Once exposed to hyperoxia at early stages of life, subjects are more likely to develop pulmonary hypertension as the changes in lung growth add strains on the cardiovascular system4. By measuring right ventricular pressure (RVP) through catheterization and quantifying the Pressure-Volume (PV) loops of the RVP, the severity of the associated pulmonary hypertension can be measured.


The emka & SCIREQ team will be attending the American Thoracic Society’s 2017 conference in Washington, D.C.! Come visit our booth #1731 and speak with our experienced team about our solutions for preclinical pediatric research.

1 Caffeine Prevents Hyperoxia-Induced Functional and Structural Lung Damage in Preterm Rabbits – Toelen et al. Neonatology. 109:274, 2016
2 Characteristics of asthma and airway hyper-responsiveness after premature birth – Oymar et al. Pediatr Allergy Immunol., 16: 487, 2005
3 Neonatal Hyperoxia Causes Pulmonary Vascular Disease and Shortens Life Span in Aging Mice – O’Reilly et al. Am J Physiol., 17:2601, 2011
4 Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor – Abman et al. Am J Physiol Lung Cell Mol Physiol. 283:L555, 2002


Tuesday, May 2, 2017

WORLD ASTHMA DAY


The first Tuesday in May is marked as World Asthma Day by the Global Initiative for Asthma. This is an annual event with a goal to improve asthma awareness and care around the world. According to World Health Organization (WHO) estimates, 235 million people suffer from asthma and it’s the most common chronic disease among children. Asthma can be both chronic and heterogeneous and is often associated with allergies to airborne antigens. WHO also notes that asthma affects people in all countries around the world regardless of development1.


Learn more about SCIREQ's solutions for Asthma research.
 
Assessing airway responsiveness in response to aerosol challenges is the most frequently reported outcome for asthma research. When equipped with an integrated nebulizer, the flexiVent can be used to both deliver aerosol challenges to a subject’s lungs and follow the developing bronchoconstriction through automated data collection.


Thank You to all researchers and health care providers who are striving to develop effective treatments for this condition.

1World Health Organization. "10 facts on Asthma" http://www.who.int/features/factfiles/asthma/en//

Tuesday, April 11, 2017

JOIN OUR TEAM AT THE EXPERIMENTAL BIOLOGY 2017 CONFERENCE IN CHICAGO!

The emka & SCIREQ team will be attending the Experimental Biology 2017 conference in Chicago! We will present and demonstrate our wide range of preclinical instruments for neuro, pulmonary and cardio studies. Come by booth 315 and speak with our experienced team about our solutions for physiology, pharmacology and toxicology research.

A special focus on sleep studies with whole body plethysmography

Plethysmography utilizes a non-invasive technique which allows conscious polysomnography, or sleep studies, in unanaesthetized, spontaneously breathing subjects. This technique provides continuous high-fidelity respiratory recordings during sleep and wakefulness based on measures of tidal volume, respiratory rate and minute ventilation.


BENEFITS FOR SLEEP STUDIES
  • Easy-to-use, no surgery required
  • Does not require anaesthetics, which can depress the neural-network controlling respiration
  • Freely moving subjects, limiting stress-related changes in respiration due to restraints
  • Conscious, ability to respond to real-time changes
  • Plethysmography systems may also integrate with a mass flow controller to measure these respiratory effects under chronic intermittent periods of hypoxia, a key feature of sleep apnea.

EASY INTEGRATION WITH CARDIO AND NEURO PARAMETERS
Integration of electroencephalogram (EEG), electrocardiogram (ECG) & electromyogram (EMG) recordings with respiratory signals offer a detailed characterization of the neurological and cardiopulmonary contributions in a sleep-disordered breathing state.


IOX SOFTWARE HIGHLIGHTS
  • Measures ventilatory parameters: Respiratory Rate (RR), estimated Tidal Volume (VT), Minute Ventilation (V) or Periodic breathing
  • Specific apnea analyzer for counting and analyzing apneas which can be precisely tuned for breath to breath acceptance or rejection
  • Automated alarms when clinically relevant physiologic triggers are reached
  • Gas mixture delivery (O2, CO2 and N2) can be automated through IOX software with protocols for evaluation of hypoxia, hyperoxia and hypercapnia.


TELEMETRY
easyTEL implantable system transmits physiological data from conscious freely moving laboratory animals. Our range of implants offers the ability to record the following parameters, depending on your study needs:
  • Biopotential (ECG, EEG, EMG)
  • Blood pressure
  • Temperature
  • Activity from acceleration



Click here to schedule a meeting with one of our specialists during EB 2017.
 
Exhibit Hours
Sunday, April 23rd - 9:00am to 4:00pm
Monday, April 24th - 9:00am to 4:00pm
Tuesday, April 25th - 9:00am to 4:00pm


Thursday, April 6, 2017

The End of an Era - retiring our legacy flexiVent System


Our legacy flexiVent system has officially retired starting March 1st, 2017.
The first legacy flexiVent system was introduced by SCIREQ in 1997 and some of these units are still being used to this day, almost 20 years later! During this time the flexiVent system has been used in pulmonary research applications, as an integral part of studies all over the globe, to generate accurate and consistent data related to lung mechanics.

Over the past few years it has become more difficult to support our legacy systems, with considerable rises in costs associated with maintenance and support for existing systems. After careful consideration, it was decided to retire the legacy flexiVent.
Should you come across issues when working with you flexiVent system, you may contact our technical support team at techsupport@scireq.com for assistance with acquiring relevant technical support documents which may assist you with troubleshooting the issue. However, as the legacy flexiVent system is no longer supported, it would not be possible to send the legacy components back to SCIREQ for repair. Further, due to limited resources in sourcing parts, replacement components are no longer available for purchase.
The updated flexiVent FX system was introduced in 2010.
 
We listened to your feedback and are pleased to inform you that in addition to including all the pre-existing features and capabilities of the legacy system, many significant improvements and features have been included into the flexiVent FX system. Some of the technical enhancements in the new flexiVent FX system include the use of field serviceable modules, significant reduction in noise during use, increased data accuracy as well as the possibility to now measure additional outcomes such as lung volumes.

Since being introduced, the flexiVent FX system has been used worldwide with constant improvements being made on the system by our development team which will further assist you in meeting your research goals.
If you are a legacy flexiVent system user and would like additional information regarding the new flexiVent FX new system, please feel free to contact us at sales@scireq.com or toll free at 1.877.572.4737. Our Application specialists would be happy to address any questions or concerns that you may have.
 

Thursday, March 9, 2017

JOIN US AT THE SOCIETY OF TOXICOLOGY MEETING IN BALTIMORE!

The emka & SCIREQ team will be attending the 2017 Society of Toxicology conference in Baltimore. We will be demonstrating our wide range of preclinical instruments for neuro, pulmonary and cardio studies. Come by booth #1622 and speak with our experts about our solutions for physiology, pharmacology and toxicology research.

Come see our new E-cigarette exposure solution!
 

E-cigarette vapour composition is influenced by a number of factors, some relating to the device physically (battery charge, wattage/temperature control, puffing profile) and others relating to the e-liquid (proportion of propylene glycol and glycerol, amount of nicotine, pH of solution). Standardizing how we study E-cigarettes will be key to understanding their impact. 

 

Our E-cigarette extension offers:
»       Automated programmable puffing profiles for repeatability between studies and across laboratories.
»       Adapted power supply for stable voltage output and coil resistance providing consistent vapour generation.
»       Wattage and temperature control to maintain precise vapour density.
»       Large E-liquid tank for longer duration exposures.
»       Accessible tank for easy top-up to maintain level of E-liquid and avoid undesired decomposition.
 
Exhibit Hours
Monday, March 13th - 9:15am to 4:30pm
Tuesday, March 14th - 9:15am to 4:30pm
Wednesday, March 15th - 9:15am to 4:30pm
 


Click here to schedule a meeting with one of our experts during SOT 2017.

Thursday, February 2, 2017

Asthma - from mouse to man




“The assessment of lung function endpoints used in preclinical drug testing may hold the key to translation of drug efficacy from mouse to man1.”

Bench-to-bedside
Mouse models have been and continue to be of invaluable importance in asthma research, for the elucidation of key disease pathways as well as in the assessment of potential therapies2. While therapeutic candidates showing promise in murine models have not always translated into clinical successes, the story behind the recent FDA-approved anti-IL-5 and anti-IL-13 therapies3, previously deemed ineffective in general asthmatic populations, is a compelling example of how a better understanding of both the underlying disease mechanisms and the models resulted into “bench-to-bedside” achievements.


Mouse models of asthma
Asthma is a complex heterogeneous disease whose features have not been completely depicted by any single mouse disease model.  In preclinical (in vivo) research, careful considerations should be given to the model employed, its phenotype, as well as the measured outcomes.  Ideally, studies should include outcomes with strong predictive or translational value such as lung function measurements.  Respiratory function outcomes are often considered as primary study endpoint in many clinical trials targeting asthma patients. Therefore, relying on robust lung function measurements early on in the preclinical validation and development of potential disease targets and therapeutic candidates can, not only avoid misleading assessments, but also provide a grounded approach to support the critical program decision-making process.


Lung function outcomes
Lung function outcomes provided by SCIREQ‘s flexiVent and plethysmography methodologies aim to bridge the gap between mouse and man.  Referenced in thousands of peer-reviewed scientific publications and patents4, our scientific instruments permit accurate and detailed measurements to complement and strengthen biochemistry or immunology data.  These measurements are conveniently combined into a robust and comprehensive pulmonary assessment, collected via a computer-controlled instrument that also maximizes reproducibility.

Future direction
Mouse models represent a highly valuable tool to study the mechanisms involved in asthma and extrapolate scientific discoveries to humans.  The translatability of the information provided will only be ensured in the future by the continuous refinement of the models employed, as well as by a holistic approach combining lung mechanics data to a comprehensive assessment of the model phenotype.  This rigorous approach will hopefully help identify target populations and lead to additional success stories in the clinic, benefiting asthma patients worldwide.

Relevant links:


Tuesday, January 17, 2017

Together for Respiratory Research

January 15 to 21st is National Non-Smoking Week (NNSW) in Canada and we would like to take this opportunity to highlight the efforts of researchers, here and around the world, to deepen our knowledge on the health effects of smoke. Their work builds the scientific evidence to guide today’s and tomorrow’s decisions on the use of tobacco and tobacco-related products.  At SCIREQ, we understand respiratory research and take pride in assisting researchers in their task by providing precision laboratory instruments that enable them to achieve their scientific goals.

We believe that together we can make a difference.  

Read more